文献速递胸部肿瘤

局限期小细胞肺癌成功治疗后继发恶性肿瘤的发生率及其对生存的影响

Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival.
PubMed 文献 · J Thorac Oncol · 2017-08-10

本研究纳入1985年至2012年在单一机构接受至少45 Gy放疗联合化疗的局限期小细胞肺癌患者,评估成功治疗后异时性第二恶性肿瘤(MSM)的发生率,并比较发生MSM与未发生者的生存。541例可评估患者中15例(2.8%)发生MSM,MSM患者总生存长于无其他恶性肿瘤且无复发者,10年生存率分别为61.9%与29.9%(p=0.03)。

要点

  • 541例可评估患者中15例(2.8%)发生MSM,其中13例位于肺(8例腺癌、5例鳞状细胞癌)。
  • MSM患者10年总生存率61.9%,无其他恶性肿瘤且无复发者为29.9%(p=0.03)。
  • 作者认为小细胞肺癌长期生存者应了解MSM风险及随访的必要性。

核心结论

  • 局限期小细胞肺癌成功治疗后的长期生存者中可发生MSM,本组发生率为2.8%,MSM患者的总生存长于无其他恶性肿瘤且无复发者。

研究设计与样本

  • 单机构研究,纳入1985年至2012年诊断为局限期小细胞肺癌且接受至少45 Gy放疗和化疗的患者。
  • MSM定义为出现在小细胞肺癌诊断2年之后、组织学类型与原发肿瘤不同的肿瘤。
  • 共识别704例患者,排除因缺乏随访32例、因小细胞肺癌为其他癌症治疗后的MSM 48例、因非黑色素瘤皮肤癌作为MSM 37例、因MSM出现在小细胞肺癌诊断后2年内46例,余541例纳入分析。

主要发现

  • 541例中346例小细胞肺癌复发,180例无第二恶性肿瘤且无复发,15例(2.8%)发生MSM。
  • 15例MSM中13例位于肺(8例腺癌、5例鳞状细胞癌),1例肉瘤,1例急性髓系白血病。
  • 15例MSM患者均对小细胞肺癌治疗达到完全缓解。
  • MSM患者10年总生存率为61.9%(95%CI:30.0%-82.6%),无其他恶性肿瘤且无复发者为29.9%(95%CI:21.5%-38.6%),p=0.03。

临床怎么用

  • 原文结论指出,小细胞肺癌治疗后的长期生存者应了解MSM风险及随访的必要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Extended survival outcomes from improved treatments for patients with cancer come with an increased risk for development of a metachronous second malignancy (MSM). We evaluated the incidence of MSM after successful treatment of SCLC and compared survival between patients with SCLC in whom MSM developed and those in whom it did not. METHODS: Selection criteria were a diagnosis of limited-stage SCLC and receipt of at least 45 Gy of radiotherapy and chemotherapy at a single institution in 1985-2012. MSM was defined as a tumor of a different histologic type than the primary that appeared more than 2 years after the diagnosis of SCLC. RESULTS: Of 704 patients identified, 32 were excluded for lack of follow-up, 48 for having SCLC as MSM after treatment of another type of cancer, 37 for nonmelanoma skin cancer as MSM, and 46 for MSM within 2 years after SCLC diagnosis. Of the remaining 541 patients, 346 had recurrent SCLC, 180 had no second malignancy and no recurrence, and 15 (2.8%) had MSM (13 in a lung [eight adenocarcinomas and five squamous cell carcinomas], one sarcoma, and one acute myeloid leukemia). All 15 patients with MSM achieved complete response to the SCLC treatment. Overall survival was longer for patients with MSM than for patients with no other malignancies and no recurrence, with 10-year rates of 61.9% (95% confidence interval: 30.0%-82.6%) and 29.9% (95% confidence interval: 21.5%-38.6%), respectively (p = 0.03). CONCLUSIONS: Long-term survivors after treatment for SCLC should be made aware of the risk for MSM and the necessity of follow-up.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Kono M, Allen PK, Lin SH, et al. Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival. J Thorac Oncol. 2017. PMID: 28804012. doi:10.1016/j.jtho.2017.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。